BiotechTube
OncoLize

OncoLize

Amsterdam, Netherlands· Est.
oncolize.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

OncoLize is a private, pre-clinical stage biotech developing an injectable polymer-based hydrogel platform (ChemoGell™) for the intratumoral delivery of proven chemotherapy drugs. The technology aims to concentrate drugs inside the tumor, enhancing efficacy and minimizing systemic toxicity. Having secured €1.6M in seed funding and demonstrated promising preclinical results, including 100% survival in a pancreatic cancer PDX model, the company is preparing for a Series A round of €8-10M in late 2024 to advance into clinical trials by 2026.

Oncology

Technology Platform

Polymer-based hydrogel platform (ChemoGell™) for localized, slow-release intratumoral drug delivery.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

The high unmet need in aggressive cancers like pancreatic cancer presents a significant market opportunity.
The platform's ability to enhance generic drugs offers a cost-effective development path and aligns with global affordability goals.
Successful proof-of-concept in lead indication could enable rapid portfolio expansion into other solid tumors.

Risk Factors

High translational risk moving from compelling preclinical data to human trials.
The company is dependent on raising a substantial Series A round in a tight funding environment.
It faces competition from other localized delivery technologies and must successfully navigate regulatory pathways for a novel drug-device combination product.

Competitive Landscape

OncoLize operates in the competitive field of localized drug delivery for oncology, competing with other companies developing injectable depots, implants, and targeted delivery systems. Its key differentiators are the focus on simplicity, affordability, and the use of proven generic chemotherapeutics, which may allow for faster development and lower costs compared to platforms using novel drug compounds.

More companies in Drug Delivery & Formulation →More companies in Netherlands →